Panbela Therapeutics, Inc. (PBLA)

Market Cap	1.99M
Revenue (ttm)	n/a
Net Income (ttm)	-20.75M
Shares Out	4.85M
EPS (ttm)	-259.50
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,382
Open	0.475
Previous Close	0.420
Day's Range	0.410 - 0.490
52-Week Range	0.400 - 477.000
Beta	0.78
Analysts	Strong Buy
Price Target	15.00 (+3,557.64%)
Earnings Date	May 2, 2024

About PBLA

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, develops disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; FlynpoviTM, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 7
• Stock Exchange: OTCMKTS
• Ticker Symbol: PBLA

Analyst Forecast

According to 2 analysts, the average rating for PBLA stock is "Strong Buy." The 12-month stock price forecast is $15.0, which is an increase of 3,557.64% from the latest price.

Price Target

$15.0

(3,557.64% upside)

Analyst Consensus: Strong Buy